Protagenic Therapeutics Stock Today
Protagenic Therapeutics is selling for under 0.0091 as of the 20th of September 2024; that is 41.67 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.009. Equity ratings for Protagenic Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of April 2024 and ending today, the 20th of September 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of April 2021 | Category Healthcare | Classification Health Care |
Valuation Profit Patterns
Check how we calculate scores
Protagenic Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Materials, Materials (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Protagenic Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Protagenic Therapeutics' financial leverage. It provides some insight into what part of Protagenic Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Protagenic Therapeutics (PTIXW) is traded on NASDAQ Exchange in USA. It is located in 149 Fifth Avenue, New York, NY, United States, 10010 and employs 1 people. Protagenic Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry.
Protagenic Therapeutics has accumulated about 671.09 K in cash with (3.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Protagenic Therapeutics Probability Of Bankruptcy
Protagenic Therapeutics Historical Income Statement
Protagenic Stock Against Markets
Protagenic Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Protagenic Therapeutics stock to make a market-neutral strategy. Peer analysis of Protagenic Therapeutics could also be used in its relative valuation, which is a method of valuing Protagenic Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Protagenic Therapeutics Corporate Management
| Robert Stein | Chief Director | Profile | |
| CFA MD | CFO Sec | Profile | |
| Garo Armen | CoFounder Chairman | Profile | |
| David Lovejoy | Scientific Officer | Profile | |
| Andrew Slee | Chief Officer | Profile |
Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.